Retrospective study of selegiline-antidepressant drug interactions and a review of the literature

Annals of Clinical Psychiatry

Volumn 9, Issue 1, 1997, Pages 7-13

  Ritter, Janet L ^a   Alexander, Bruce ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Bupropion; Drug interactions; Selective serotonin reuptake inhibitors; Selegiline; Tricyclic antidepressants

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CARBIDOPA PLUS LEVODOPA; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGED; AMNESIA; ANXIETY NEUROSIS; ARTICLE; BRAIN HEMORRHAGE; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DREAM; DROWSINESS; DRUG CONTRAINDICATION; DRUG FATALITY; FALLING; FATIGUE; HALLUCINATION; HUMAN; HYPERPYREXIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESTLESSNESS; RETROSPECTIVE STUDY; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; TREMOR; VERTIGO; VOMITING; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPARKINSON AGENTS; BUPROPION; COMORBIDITY; DEPRESSION; DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SELEGILINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0030807313     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026222106851     Document Type: Article

References (37)

1. Suchowersky O, deVries J: Possible interactions between Deprenyl and Prozac [letter]. Can J Neurol Sci 1990; 17:352-353
2. Blackwell B: Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991; 11:55-59
3. Davies G: Side effects of phenelzine [letter]. Br Med J 1960; 2:1019
4. Singh H: Atropine-like poisoning due to tranquilizing agents [letter]. Am J Psychiatry 1960; 117:360-361
5. Howarth E: Possible synergistic effects of the new thymoleptics in connection with poisoning. J Ment Sci 1961; 107:100-103
6. Ayd FJ: Toxic somatic and psychopathologic reactions to antidepressant drugs. J Neuropsychiatry 1961; 2:S119-S122
7. Selegiline (Eldepryl) Package Insert: Somerset Pharmaceuticals; Sept 1994
8. Sternbach H: The serotonin syndrome. Am J Psychiatry 1991; 148:705-713
9. McCurdy RL, Kane FJ: Transient brain syndrome as a non-fatal reaction to combined pargyline-imipramine treatment. Am J Psychiatry 1964; 121:397-398
10. Brachfeld J, Wirtschafter A, Wolfe S: Imipramine-tranylcypromine incompatibility [letter]. JAMA 1963; 186:1172-1173
11. Kane FJ, Freeman D: Non-fatal reaction to imipramine-MAO inhibitor combination [letter]. Am J Psychiatry 1963; 120:79-80
12. Babiak W: Case fatality due to overdosage of a combination of tranylcypromine and imipramine [letter]. Can Med Assoc J 1961; 85:377
13. Bowen LW: Fatal hyperpyrexia with antidepressant drugs. Br Med J 1964; 2:1465-1466
14. Ponto LB, Perry PJ, Liskow BI, Seaba HH: Drug therapy reviews: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 1977; 34:954-961
15. Blackwell B, Marley E, Price J: Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967; 113:349-365
16. Goldberg RS, Thornton WE: Combined tricyclic-MAOI therapy for refractory depression: A review, with guidelines for appropriate usage. J Clin Pharmacol 1978; Feb.-Mar.:143-147
17. DRUGDEX Editorial Staff: Levodopa-tricyclic antidepressant interaction (drug consult). In: Gelman CR, Rumack BH, eds. DRUGDEX Information System. Denver: Micromedex (edition expired 5/90)
18. Graber MA, Hoehns B, Perry PJ: Sertraline-phenylzine drug interaction: A serotonin syndrome reaction. Ann Pharmacother 1994; 28:732-735
19. Brannan SK, Talley BJ, Bowden CL: Sertraline and isocarboxazid cause a serotonin syndrome [letter]. J Clin Psychopharmacol 1994; 14:144-145
20. Beasley CM, Masica DN, Heiligenstein JH, et al.: Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993; 13:312-320
21. Bhatara VS, Bandettini FC: Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993; 12:222-225
22. Coplan JD, Gorman JM: Detectable levels of fluoxetine metabolites after discontinuation: An unexpected serotonin syndrome [letter]. Am J Psychiatry 1993; 150:837
23. Jermain DM, Hughes PL, Follender AB: Potential fluoxetine-selegiline interaction [letter]. Ann Pharmacother 1992; 26:1300
24. Montastruc JL, Chamontin B, Senard JM, et al.: Pseudophaechromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341:555
25. Sternbach H: Danger of MAOI therapy after fluoxetine withdrawal [letter]. Lancet 1988; Oct:850-851
26. Toyama SC, Iacono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? [letter]. Ann Pharmacother 1994; 28:405-406
27. Abuzzahab FS: Combination therapy: Monoamine oxidase inhibitors and bupropion HCL [abstract]. Neuropsychopharmacology 1994; 10(35, Part 2):74S
28. Dooneief G, Mirabello E, Bell K, et al.: An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992; 49:305-307
29. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG: Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178:27-31
30. Andersen J, Aabro E, Gulmann N, et al.: Antidepressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980; 62:210-219
31. Ahlskog JE: Parkinson's disease: Update on pharmacologic options to slow progression and treat symptoms. Hosp Formul 1992; 27:146-163
32. Cohen G, Spina MB: Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26:689-690
33. Hurley SC: Tricyclic antidepressants-induced abnormal movements (drug consult). In: Gelman CR, Rumack BH, eds. DRUGDEX Information System. Denver: Micromedex (edition expired 5/90)
34. DRUGDEX editorial staff. Amoxapine (drug evaluation monograph). In: Gelman CR, Rumack BH, eds. DRUGDEX Information System. Denver: Micromedex (edition expired 5/90)
35. Fahn S: Parkinsonism. In: Wyngaarden JB, Smith LH, eds. Cecil Textbook of Medicine, 18th ed. Philadelphia: WB Saunders; 1988:2143-2147
36. Strang RR: Imipramine in treatment of parkinsonism: A double-blind placebo study. Br Med J 1965; 2:33-34
37. Laitinen L: Desipramine in treatment of Parkinson's disease. Acta Neurol Scand 1969; 45:109-113